Illumina offers a broad portfolio of cancer panels and cancer-focused products across multiple application areas. These products have been optimized with clinical cancer research in mind.
Achieve sequence-ready libraries from as little as 1 ng of high-quality input or 10 ng formalin-fixed paraffin-embedded (FFPE) sample using efficient, optimized assays and integrated sequencing and bioinformatics. Our comprehensive offering includes both fixed panels and custom options.
AmpliSeq for Illumina and our TruSight cancer panels offer several library preparation, sequencing, and data analysis options for cancer research. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. Illumina systems deliver industry-leading sequencing—in fact, more than 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*
Select your application area below to find out more about our product offerings for cancer research.
TruSight Oncology 500
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
TruSight Tumor 170
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
TruSight Oncology UMI Reagents
The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.
AmpliSeq for Illumina Focus Panel
Targeted DNA and RNA panel investigating 52 genes with known relevance to solid tumors.
AmpliSeq for Illumina Comprehensive Panel v3
Targeted DNA and RNA panel investigating variants across 161 genes associated with a range of cancer types.
TruSight Tumor 15
Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.
TruSight RNA Fusion
Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.
AmpliSeq for Illumina Cancer Hotspot Panel v2
Targeted panel investigating hotspot regions of 50 genes with known associations to cancer.
AmpliSeq for Illumina Comprehensive Cancer Panel
Targeted panel investigating the exonic regions of 409 genes with known associations to cancer.
AmpliSeq for Illumina Custom Panel
Targeted custom panel optimized for specific targets or genomic content of interest.
Desktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.
MiSeqDx System in Research Mode
FDA-cleared in vitro diagnostic NGS system that also operates in research mode to generate accurate, reliable data.
Simple, affordable solution for low-throughput targeted cancer sequencing.
NextSeq 550 System
Sequencing and cytogenomic array scanning on a single system, with a seamless transition between applications.
NextSeq 550Dx System in Research Mode
FDA regulated, CE-IVD, next-generation sequencing system that also runs in research mode to enable high-throughput clinical research.
iSeq 100 System
Affordable, fast, and accessible sequencing power for targeted or small genome sequencing in any lab.
Local Run Manager
Easy-to-use software for automated on-instrument data analysis.
BaseSpace Sequence Hub
The Illumina genomics computing environment for NGS data analysis and management.
A powerful analysis and reporting tool that provides biological insight into genomic variant data.
Multi-Site Analytical Validation of TruSight Tumor 15 (TST15) Determining Robustness and ConcordanceRead Paper
Researchers are using the TruSight RNA Pan-Cancer Panel to understand the role of fusion genes in pediatric leukemia.Read Article
Dr Ravindra Kolhe and his team use TruSight Tumor 170 to study a wide number of variants associated with solid tumors.Read Article
*Data calculations on file. Illumina, Inc. 2017.